… have emerged as a new promising target for cancer therapy. This review will … of tyrosine
kinases in cancer and the development of specific tyrosine kinase blockers for cancer therapy …

… types of targeted therapy are available, but this review focuses in particular only on small
molecule tyrosine kinase inhibitors. Three have been approved for use in cancer therapy, and …

… ), the p210 Bcr-Abl is a constitutively active cytoplasmic tyrosine kinase present in virtually
all … It is a model target for cancer therapy, because the Bcr-Abl tyrosine kinase by itself is …

… and regarded as attractive therapeutic candidates. By April 2017, among the 35 protein
kinase inhibitors (PKIs) approved, 31 are used in cancer therapy [14]. For example, sorafenib, …

… of tyrosine kinase inhibitors has increased in the last few years. New receptor and non-receptor
tyrosine kinases … -receptor (EGFR) tyrosine kinase has been developed and successfully …

… Several protein kinase inhibitors have been approved by FDA in the last few decades. …
protein kinase inhibitors as of December 2017 for the well-known oncogenic protein kinases. A list …

… of inhibitors in the ATP-binding site of protein kinases have … design of tyrosine as well as
serine/threonine kinase inhibitors. It has … of protein kinases is an exciting target for the design of …

… tyrosine kinase inhibitors have emerged as important therapeutic agents in the treatment
of … The recent development of several selective TKIs for cancer therapy has already had a …

… of new drugs with tyrosine kinase blockers for cancer treatment. … tyrosine kinases blockers
effective in cancer treatment. Future treatment regiments are likely to include multiple tyrosine …

… treatment with high concen- discussion of recombinant monoclonal antibody cancer therapy
… use of low molecular weight tyrosine kinase inhibitors, which were capable of competitively …